1. Remis RS, Alary M, Liu J, Kaul R, Palmer RWH. HIV transmission among men who have sex with men due to condom failure. PLOS ONE 2014; 9: e107540.
  2. Australian Clinical Supervision Association (ACSA). Clinical Supervision: A Working Definition. ACSA Definitions Report. Forest Lake, Qld, 2014. URL (last accessed on 30 October 2019):
  3. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. New Engl J Med 1997; 337: 1485-1490.
  4. Irvine C, Egan KJ, Shubber Z, et al. Efficacy of HIV postexposure prophylaxis: systematic review and meta-analysis of nonhuman primate studies. CID 2015; 60: S165-S169.
  5. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.  New Engl J Med 1994; 331: 1173-1180.
  6. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. AIDS 2008; 22: 973–981.
  7. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. New Engl J Med 2011; 365: 493-505.
  8. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New Engl J Med 2010; 363: 2587-2599.
  9. Baeten JM, Donnell D, Ndase P, et al. Antriretroviral prophylaxis in heterosexual men and women. New Engl J Med 2012; 367: 399- 410.
  10. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet 2013; 381:2083-2090.
  11. Attia S, Egger M, Muller M, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397–1404.
  12. Gilliam BL. Methods of culturing HIV-1 from semen. Methods Mol Med 1999; 17:51–57.
  13. Dyer JR, Gilliam BL, Eron JJ Jr, et al. Quantitation of human immunodeficiency virus type 1 RNA in cell-free seminal plasma: comparison of NASBA with Amplicor reverse transcription-PCR amplification and correlation with quantitative culture. J Virol Methods 1996; 60:161–170.
  14. Vernazza PL, Gilliam BL, Flepp M, et al. Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS 1997; 11:1249–1254.
  15. Pereira AS, Kashuba AD, Fiscus SA, et al. Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden. J Infect Dis 1999; 180:2039–2043.
  16. Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000; 14:415–421.
  17. Townsend CL, Byrne L, Cortina-Borja M, et al. Earlier initiation of ART and further
  18. decline in mother-to-child HIV transmission rates, 2000-2011. AIDS 2014; 28:1049-1057.
  19. Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless
  20. sex in serodifferent gay couples with the HIV-positive partner taking suppressive
  21. antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational
  22. study. Lancet 2019; 39310189):2428-2438.
  23. Bavinton BR, Jin F, Prestage G, et al. The Opposites Attract Study of viral load, HIV
  24. treatment and HIV transmission in serodiscordant homosexual male couples: design and
  25. methods. BMC Public Health. 2014; 14:917.
  26. Center for Disease Control and Prevention. Updated U.S Public health service guidelines for the management of occupational exposures to HBV, HCV and HIV and recommendations for postexposure prophylaxis. MMWR 2001; Vol. 50, issue RR‐11.
  27. Centers for Disease Control and Prevention. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood-France, United Kingdom, and United States, January 1988-August 1994. MMWR 1995; 44:929–933.
  28. Australian Government Department of Health and Ageing. National guidelines for post-exposure prophylaxis after non-occupational exposure to HIV. URL (last accessed on 25 April 2018):
  29. Roland ME, Neilands TB, Krone M et al. Seroconversion following non-occupational postexposure prophylaxis against HIV. Clin Infect Dis 2005; 41:1507-1513.
  30. Jochimsen EM, Luo CC, Beltrami JF, et al. Investigations of possible failures of postexposure prophylaxis following occupational exposures to human immunodeficiency virus. Arch Intern Med 1999; 159:2361-2363.
  31. Tsai C-C, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl)adenine treatment for prevention of persistent simian immunodeficiency virus SIVmneinfection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72:4265-73.
  32. Roland ME, Neilands TB, Krone M,  et al. Seroconversion following non-occupational postexposure prophylaxis against HIV. Clin Infect Dis 2005; 41:1507-1513.
  33. Ford N, Irvine C, Shubber Z, et al. Adherence to HIV postexposure prophylaxis: a systematic review and meta-analysis. AIDS 2014; 28:2721-2727.
  34. Ford N and Mayer KH for the World Health Organization postexposure prophylaxis guideline development group. World Health Organization guidelines on postexposure prophylaxis for HIV: recommendations for a public health approach. CID 2015; 60:S161-S163.
  35. Post-exposure prophylaxis to prevent HIV infection. Joint WHO/ILO guidelines on post-exposure prophylaxis (PEP) to prevent HIV infection Geneva, Switzerland. WHO, 2007. URL (last accessed on 25 April 2018):
  36. McAllister J, Read P, McNulty A, Tong WWY and Carr A. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence. HIV Med 2014; 1:13-22.
  37. Foster R, McAllister J, Read TR, et al. Single-Tablet Emtricitabine-Rilpivirine-Tenofovir as HIV Postexposure in Men Who Have Sex with Men. Clin Infect Dis 2015; 61:1336-41.
  38. McAllister J, Towns J, McNulty A et al. Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV post-exposure prophylaxis in gay and bisexual men [abstract]. In: Proceedings of 21st International AIDS Conference; 2016, Jul 18-22; Durban, South Africa: Abstract WEPEC231.
  39. Truvada Prescribing information. Gilead Sciences, Inc. Foster City, CA 94404. URL (last accessed on 30 October 2019):
  40. Grulich AE, Guy R, Amin J et al, EPIC-NSW research group. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Lancet HIV. 2018; 5:e629-e637.
  41. NSW Government eHealth. Rural eHealth. URL(last accessed on 24 August 2019):